Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis-Reference-Cited by-同舟云学术

Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis

Published:2020-08 Issue:2 Volume:72 Page:729-741
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Chen Wei¹²,Yang Aiting¹²,Jia Jidong³,Popov Yury V.⁴^ORCID,Schuppan Detlef⁴⁵,You Hong¹²³

Affiliation:

1. Experimental and Translational Research Center Beijing Friendship Hospital Capital Medical University Beijing China

2. Beijing Key Laboratory of Tolerance Induction and Organ Protection in Transplantation Beijing Friendship Hospital Capital Medical University Beijing China

3. Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis National Clinical Research Center of Digestive Diseases Liver Research Center Beijing Friendship Hospital Capital Medical University Beijing China

4. Division of Gastroenterology Beth Israel Deaconess Medical CenterHarvard Medical School Boston MA

5. Institute of Translational Immunology and Research, Center for Immunotherapy University of Mainz Medical Center Mainz Germany

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31236

Reference71 articles.

1. Liver cirrhosis

2. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

3. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection